Skip to main content

Labcorp Message (as of July 21, 4:00 p.m. ET)

  • All Labcorp core systems impacted by the CrowdStrike issues are currently back online.
  • Some of our patient service centers and in-office labs may be experiencing technical issues with retrieving orders.
  • We are working hard to resolve this issue.
  • If you have a copy of your order, this will help expedite the process.
  • We appreciate your patience as we work to restore business operations.

Why work with us

Our relentless investment in technology, automation and capacity gives you access to unrivaled laboratory science and scale. Labcorp has supported each of the 50 top-selling drugs in the world. With our laboratories and kit production facilities across the globe, you can reach every geography. We strive to be your laboratory of choice at all stages of drug development and commercialization, and to transition rapidly and seamlessly through each stage. We’re ready for what’s next.

Insights driven by experience: Five decades of drug development leadership

More than 14,000 strong worldwide, Labcorp colleagues support biopharmaceutical customers, investigator sites and patients. From drug discovery to clinical trial testing and diagnostic development and commercialization, today’s Labcorp combines the innovations of more than five decades supporting our biopharma partners in bringing new therapies to patients.  

 

Rich history

Labcorp acquired drug development provider Covance in 2015, creating a market leader in healthcare laboratory services. Covance itself was formed through a rich tapestry of capabilities and acquisitions, ranging from the 1925 formation of the Wisconsin Alumni Research Foundation on the University of Wisconsin-Madison campus to Hazelton Laboratories to Corning.

In July 2023, Labcorp spun off the clinical business, now operating as Fortrea, retaining the worldwide laboratory network to deliver laboratory solutions to the world pursuing breakthrough therapeutics.

Labcorp scientist wearing PPE with a petri dish in her hand

Expanding your global reach

Labcorp has grown its footprint further within drug development, with key acquisitions of Envigo CRS and Global Specimen Solutions, as well as partnerships such as our Japan central lab relationship with BML.

We have invested substantially in advanced technology, laboratory automation and site expansions in North America, Europe and the Asia-Pacific region, including in Singapore, India and China.

Today, we serve thousands of biotech and pharmaceutical customers worldwide—initiating more than 10,000 nonclinical studies every year and supporting trials in more than 100 countries.

Labcorp Scientist holding a pipette, wearing a mask.

Leveraging scale

As part of Labcorp, a global leader of innovative and comprehensive laboratory services, has elevated the organization’s commitment to biopharmaceutical clients, providing comprehensive nonclinical study services, central lab testing and commercialization solutions. 

Learn more about the investment and expansion efforts driving innovation in our nonclinicalclinical trial and diagnostic laboratories.

Lab scientist with a large tray of testing tubes

Scientific collaboration across the globe to advance your development program

Our dedicated scientific team across global laboratory sites helps advance your program, no matter where you are in development or how complex your asset: from small molecule and biologics to cell and gene therapies (CGTs) and antibody drug conjugates (ADCs). 

~14,000 employees worldwide
~6,200 North America
~4,700 EU/MEA
~3,100 Asia-Pacific
200+ MDs/PhDs

Expedite delivery with our global laboratory and logistics infrastructure 

With lab testing and research study sites, Labcorp is committed to helping you deliver on today’s studies and tomorrow’s promise. 

10,000+ nonclinical studies conducted each year
50%+ of industry clinical trials
5,000+ individual protocols
700+ study types in our nonclinical catalog 
2,000+ patient service centers with 6,000 in-office phlebotomists
186,000 unique clinical investigator sites globally

Let's start a conversation